Triple-Drug cocktail targets Hard-to-Treat blood cancers
NCT ID NCT07679334
First seen Jul 01, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This phase I trial is testing whether combining three drugs—pacritinib, venetoclax, and azacitidine—is safe and tolerable for people with accelerated or blast phase myeloproliferative neoplasms, aggressive blood cancers. The study enrolls about 20 adults whose disease has progressed beyond earlier stages. Researchers aim to find the best dose of pacritinib when used with the other two drugs, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pacritinib, venetoclax, and azacitidine
- What this could lead to
- If safe and effective, this combination could offer a new treatment option for people with advanced myeloproliferative neoplasms, potentially slowing disease progression.
- What could go wrong
- This is an early phase I trial with only 20 participants, so the main goal is safety and dosing, not proof of effectiveness. Side effects from the drug combination are unknown and could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLAST PHASE MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug reduce bloodletting for polycythemia vera?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a modified interferon rein in early myelofibrosis?
- Can pressurized oxygen boost cord blood transplants?
- New transplant recipe aims to tame Graft-Versus-Host disease